back to US directory
us clinical guidance

Chronic heart failure

US staging, phenotype confirmation, guideline-directed therapy, monitoring and referral priorities for adults with chronic heart failure.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults at risk for heart failure or with chronic symptomatic heart failure, classified by ACC/AHA stage and left-ventricular ejection-fraction phenotype. Acute pulmonary edema, cardiogenic shock and other decompensated presentations require the acute-heart-failure pathway; pregnancy, congenital disease and pediatric heart failure require specialist guidance.
sources for this section:AHA/ACC/HFSA 2022

The Bottom Line

  • Classify ACC/AHA stage and ejection-fraction phenotype; when ejection fraction is above 40%, objective evidence of increased filling pressures is important to confirm heart failure.
  • For HFrEF, guideline-directed medical therapy includes four foundational medication classes, one of which is an SGLT2 inhibitor; initiate and titrate as tolerated rather than waiting for sequential failure.
  • The guideline also recommends SGLT2 inhibitors for selected patients across mildly reduced and preserved ejection-fraction phenotypes, with other therapies individualized by phenotype and comorbidity.
  • Address hypertension, coronary disease, atrial fibrillation, diabetes, kidney disease, iron deficiency, sleep disorders, vaccination, exercise and self-care as part of the heart-failure plan.
  • Refer patients with advanced heart failure who wish to prolong survival to a specialist team for advanced-therapy assessment and goal-concordant palliative care.
sources for this section:AHA/ACC/HFSA 2022

Practical clinical workflow

1
Confirm the syndrome with history, examination, natriuretic peptide testing and cardiac imaging as appropriate; identify ischemic, valvular, rhythm, toxic and systemic contributors.
2
Record stage, ejection-fraction phenotype, congestion, functional limitation, kidney function, electrolytes, blood pressure and comorbidity burden.
3
Start and titrate phenotype-appropriate guideline-directed therapy, providing practical education about adherence, daily symptoms, weight, sodium, activity and when to seek help.
4
Recheck blood pressure, kidney function, potassium, volume status, symptoms and adverse effects after initiation or dose change; repeat imaging when the result will change management.
5
Assess device eligibility, cardiac rehabilitation, multidisciplinary support and timely advanced-heart-failure referral when symptoms progress despite treatment.
sources for this section:AHA/ACC/HFSA 2022

Safety boundaries and escalation

  • New rest dyspnea, hypoxemia, hypotension, confusion, chest pain, syncope, rapidly worsening edema or oliguria may signal acute decompensation and needs urgent assessment.
  • Check renal function, potassium, blood pressure, volume status and interactions when adding or titrating renin-angiotensin-system, mineralocorticoid, diuretic or SGLT2 therapies.
  • Verify pregnancy potential and current FDA labeling; several foundational HFrEF medicines can cause fetal harm.
  • Do not abruptly withdraw effective heart-failure therapy solely because ejection fraction improves; reassess the complete guideline and patient context.
sources for this section:AHA/ACC/HFSA 2022

Localization

The 2022 AHA/ACC/HFSA guideline supplies the US clinical framework. US FDA indications, insurer authorization, device coverage and local specialty access determine implementation.
sources for this section:AHA/ACC/HFSA 2022

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. American Heart Association, American College of Cardiology, and Heart Failure Society of America2022 AHA/ACC/HFSA Guideline for the Management of Heart FailureDOI 10.1161/CIR.0000000000001063 路 published 2022-04-01 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.